A nationwide recall of an arthritis infusion drug has been issued after the manufacturer found glass particles in the vials. Because the medication is administered in clinics and infusion centers rather than at home, the burden of responding falls almost entirely on health care providers.
Fresenius Kabi is recalling one lot of Tyenne, a tocilizumab-aazg injection supplied in 400 mg/20 mL vials, to the user level. The company said an internal investigation found the product contained glass particles. The announcement is dated August 10, 2026, and the FDA posted it the following day.
The affected product carries lot number 16UI07 and National Drug Code 65219-594-20, with an expiration date of August 2028. The vials shipped between March 3 and March 25 of this year and were distributed nationwide to wholesalers, distributors, and direct customers.
Particulate in an Injectable Is Treated as a Serious Defect
The reason a small amount of glass triggers a national recall is due to the delivery route. A particle swallowed in a tablet generally passes through the digestive tract. A particle delivered directly into a vein does not.
Fresenius Kabi's risk statement, published in the FDA recall announcement, describes both ends of the severity range. At the milder end, glass particulates may cause local irritation, pain or swelling at the infusion site, along with inflammation of the veins. More seriously, the company states that glass particles can cause blockage and clotting in blood vessels, cutting off blood flow to vital organs, leading to a life-threatening blood clot in the lungs and causing permanent organ damage or death.
That is the standard hazard framing for particulate contamination in an intravenous product, and it explains why the response is removal from circulation rather than enhanced inspection. Infusion staff visually inspect solutions before administration, but particles small enough to escape visual inspection can still be clinically significant.
The Patients Who Receive This Drug
Tocilizumab blocks interleukin-6 signaling and is used for a wide range of serious inflammatory conditions, making the affected patient population broader than the word arthritis suggests.
Tyenne is indicated for adults with moderately to severely active rheumatoid arthritis who did not respond adequately to disease-modifying antirheumatic drugs, adults with giant cell arteritis, patients aged 2 and older with active polyarticular juvenile idiopathic arthritis, patients aged 2 and older with active systemic juvenile idiopathic arthritis, adults and children aged 2 and older with severe or life-threatening cytokine release syndrome induced by CAR T cell therapy, and certain hospitalized adults with COVID-19.
The presence of pediatric indications matters. Children with juvenile idiopathic arthritis receive scheduled infusions, often every few weeks, and their parents track those appointments closely. So do patients with giant cell arteritis, in whom interrupted treatment carries a risk of vision loss.
Patients Are Not Being Asked to Check Anything
The recall is designated to the user level, and the practical meaning of that phrase is worth spelling out, because it differs from the recalls consumers are used to.
Fresenius Kabi is notifying distributors and customers by letter and arranging returns. Health care facilities holding the affected lot are instructed to immediately stop distributing, dispensing or using it and to return all units to the company. Distributors must notify customers who received the product or may have received it.
No patient has a vial in a medicine cabinet to inspect. The lot number appears on a vial that a pharmacy or infusion center handles, and a patient receiving an infusion generally never sees it. That distinction is the reason this recall differs from, for example, the prednisolone eye drop recall MedicalDaily covered, where the affected product sat in patients' homes, or the compounded glutathione vials pulled from a Texas pharmacy.
Patients who want reassurance can call their infusion center and ask whether the facility received lot 16UI07 and whether it was quarantined. That is a reasonable question, and clinic staff should be able to answer it. Fresenius Kabi has also opened a line for recall questions at 1-866-716-2459, available weekdays from 8 a.m. to 5 p.m. Central time.
Continuity of Treatment Is the Real Household Concern
For most patients, the larger practical issue is not exposure to glass. It is whether a quarantined lot creates a gap in scheduled dosing.
Only one lot is affected, so a supply disruption is not expected to be widespread. Patients should not skip or delay an infusion on their own based on the recall. Anyone whose appointment is rescheduled should ask the clinic for the replacement date and whether the interval is clinically acceptable for their condition, since some conditions tolerate a short delay better than others.
Patients who received an infusion of this product and experienced problems should contact their physician or health care provider. Symptoms that warrant attention include new or worsening pain, redness or swelling at the infusion site, or a firm, tender cord along the vein, which can indicate vein inflammation. Sudden shortness of breath, chest pain, coughing up blood, or a rapid heartbeat after an infusion requires urgent evaluation. Adverse reactions and product quality problems can also be reported to the FDA's MedWatch program.
Several details have not been disclosed. Fresenius Kabi has not said how many vials were in the affected lot, how the glass entered the product, or whether any patient has been injured. The FDA has not yet assigned a recall classification, which indicates how serious the agency judges the hazard to be. That classification typically follows the initial announcement by several weeks and will appear in the agency's enforcement report, as it did with a recent Class I designation for heart pump introducer kits.
Readers should watch the agency's recalls and safety alerts page for that classification and for any expansion beyond the single lot. Recalls of injectable products occasionally widen once a manufacturer completes its investigation into the source of the defect.
Key Questions Answered
What was recalled? One lot of Tyenne, a tocilizumab-aazg injection in 400 mg per 20 mL vials, made by Fresenius Kabi, was recalled after glass particles were found in the product.
Which lot is affected? Lot number 16UI07, NDC 65219-594-20, with an expiration date of August 2028. The vials were shipped between March 3 and March 25.
What is the risk from glass particles? The company says they may cause infusion site irritation, pain, swelling, and vein inflammation, and more seriously, can cause blood vessel blockage and clotting, including a life-threatening lung clot.
Do patients need to check anything at home? No. This drug is administered in clinics, hospitals, and infusion centers, so the recall response falls on health care facilities and distributors.
Who takes this medication? Patients with rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis, CAR T-cell-induced cytokine release syndrome, and certain hospitalized COVID-19 patients.
Should patients skip their next infusion? No. Only one lot is affected. Patients should keep scheduled appointments and ask the clinic whether the recalled lot was received and quarantined.
When should someone seek urgent care? Sudden shortness of breath, chest pain, coughing up blood, or a rapid heartbeat after an infusion requires urgent evaluation.
